Received May 26, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| RSV | RSV (AREXVY) | GLAXOSMITHKLINE BIOLOGICALS | UNK | UNK | — |
She got sick after the shot; Coughing; mucus; This non-serious case was reported by a consumer via interactive digital media and described the occurrence of sickness in a female patient who received RSVPreF3 adjuvanted (Arexvy) for prophylaxis. On an unknown date, the patient received Arexvy. In MAY-2026, an unknown time after receiving Arexvy, the patient experienced sickness (Verbatim: She got sick after the shot), cough (Verbatim: Coughing) and mucus discharge (Verbatim: mucus). The patient was treated with guaifenesin (Mucinex). The outcome of the sickness and mucus discharge were not reported and the outcome of the cough was resolving. It was unknown if the reporter considered the sickness, cough and mucus discharge to be related to Arexvy. It was unknown if the company considered the sickness, cough and mucus discharge to be related to Arexvy. Additional Information: GSK Receipt Date:16-MAY-2026 This case was reported by a patient via interactive digital media. The patient got sick after the shot and had mucus and coughing. It had been almost 14 days, and she had not yet gotten it checked. The mucus was thinning because she had been advised to take Mucinex. The batch number was not provided and we unable to contact the reporter.